Palleon Pharmaceuticals

Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glyco-Immune Checkpoint inhibitors to treat cancer. The companys proprietary Convergence Platform integrates technologies and insights from world-renowned scientific leaders in the fields of glycoscience and human immunology to create a novel approach to treating cancer. By targeting multiple immune cell types, Glyco-Immune Checkpoint inhibitors will tackle resistance to first-generation immuno-oncology agents, and make possible a wider range of rational combination therapies to treat cancer. While Palleon is focused primarily on oncology, the Convergence Platform is applicable to other therapeutic areas including infectious diseases, neurodegeneration, inflammation, and fibrosis. The company is...

Biotechnology,immuno-oncology,clinical development,and glyco-immune checkpoint inhibitors

Palleon pharmaceuticals operates in the Biotechnology research industry.

Palleon pharmaceuticals's revenue is 1m - 10m

Palleon pharmaceuticals has 11 - 50 employees.